| Literature DB >> 28785387 |
Farhad Bahraminia1, Seyed Reza Emadi2, Mohammad Emaneini3, Nima Farzaneh1, Mehrnaz Rad4, Babak Khoramian1.
Abstract
The macrolides appear to have considerable effects for treatment of bovine mastitis because of excellent diffusion into the mammary gland, long half-life, low protein binding, high intracellular concentration and lipid solubility. Acquired resistance to macrolides in Staphylococcus aureus is primarily related to target-site modification through acquisition of an erm gene. In the present study the prevalence of both phenotypic and genotypic tylosin resistance in S. aureus isolates (n = 103) from subclinical mastitis in nine dairy farms belonging to three different province of Iran were investigated. Overall, ermA, ermB and ermC was found in 7.80%, 32.00%, and 20.40% of S.aureus isolates, respectively. A very high percent of isolates (56.90%) were resistant to tylosin. MIC90 and MIC50 values were 64 and 32 µg mL-1, respectively. Most of tylosin resistant isolates did not harbour any erm gene but ermB was dominant gene among 58 tylosin resistant isolates of S. aureus. In overall, tylosin resistance was prevalent in S. aureus isolates obtained from bovine mastitis in Iran.Entities:
Keywords: Bovine mastitis; Macrolides; Staphylococcus aureus; Tylosin resistance; erm genes
Year: 2017 PMID: 28785387 PMCID: PMC5524549
Source DB: PubMed Journal: Vet Res Forum ISSN: 2008-8140 Impact factor: 1.054
The oligonucleotide primers and the size of amplified product used in this study
|
|
|
|
|
|---|---|---|---|
|
| F- CTGGCATATGTATGGCAATTGTT | 613 | 7 |
| R-TATTGACCTGAATCAGCGTTGTCT | |||
|
| F-TATCTTATCGTTGAGAAGGGATT | 139 | 8 |
| R-CTACACTTGGCTGATGAAA | |||
|
| F-CTATCTGATTGTTGAAGAAGCATT | 141 | 8 |
| R-GTTTACTCTTGGTTTAGGATCAAA | |||
|
| F-AATCGTCAATTCCTGCATGT | 299 | 9 |
| R-TAATCGTGGAATACGGGTTTG |
Comparison of macrolides resistant genes, tylosin resistant rates (%) and MIC (µg mL-1) distributions of S. aureus isolates.
|
|
|
|
|
|
|
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
| 33 | 1(3.03) | 1(3.03) | 7(21.21) | 0 | 0 | 3 | 0 | 0 | 1 | 2 | 5 | 16 | 5 | 1 | 32 | 64 | 0.50 - 128 | 66.67 |
|
| 40 | 6(15.00) | 21(52.50) | 13(32.50) | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 12 | 9 | 7 | 3 | 16 | 64 | 2 - 128 | 47.50 |
|
| 30 | 1(3.33) | 11 (36.67) | 1(3.33) | 0 | 0 | 4 | 0 | 1 | 2 | 2 | 4 | 9 | 4 | 4 | 32 | ≥128 | 0.50 - 128 | 56.67 |
|
| 103 | 8(7.80) | 33(32.00) | 21(20.40) | 0 | 0 | 7 | 0 | 2 | 5 | 10 | 21 | 34 | 16 | 8 | 32 | 64 | 0.50 - 128 | 56.86 |
The MIC breakpoint for tylosin (≥ 20 µg mL-1) was based on the veterinary antimicrobial decision support (VADS); MICs indicating susceptibility are exhibited on a white background, those indicating intermediate resistance on a light grey background, and those indicating resistance on a dark grey background.
Values with different superscripts in the same column are significantly different from each other (p < 0.05).
Fig. 1Agarose gel electrophoresis of PCR products of ermA and ermC. Lane 1: is 100 bp DNA ladder; Lane 2: Positive control, ermA (139 bp), ermC (299 bp); Lane 3: Negative control; Lane 4 to 13: samples
Fig. 2Agarose gel electrophoresis of PCR products of ermB. Lane 1: is 100-bp DNA ladder; Lane 2: Positive control, ermB (141bp; Lane 3: Negative control; Lane 4 to 13: samples
Distribution of erm genes in isolates
|
|
|
|
|
|---|---|---|---|
|
| 1 (1.70%) | 0 (0.00%) | 0 (0.00%) |
|
| 9 (15.50%) | 9 (29.00%) | 5 (35.70%) |
|
| 5 (8.60%) | 3 (9.70%) | 0 (0.00%) |
|
| 1 (1.70%) | 0 (0.00%) | 0 (0.00%) |
|
| 4 (6.90%) | 0 (0.00%) | 0 (0.00%) |
|
| 6 (10.30%) | 1 (3.20%) | 0 (0.00%) |
|
| 1 (1.70%) | 1 (3.20%) | 0 (0.00%) |
|
| 31 (53.40%) | 17 (54.80%) | 9 (64.30%) |